For example, in mouse models of immune-excluded breast and colorectal cancers, a co-treatment with anti-TGFβ and anti-PDL1, immune-suppressor expressed by CAFs, results in a decrease in matrix-remodeling factors, an increase in T cell reaching the tumor site, and tumor regression [119,120]. This evidence concerns the gene TGFB1 and neoplasm.